Tafinlar and Metastatic neoplasm - a phase IV clinical study of FDA data

Summary:

Metastatic neoplasm is reported as a side effect among people who take Tafinlar (dabrafenib mesylate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Mekinist, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Metastatic neoplasm when taking Tafinlar. It is created by eHealthMe based on reports of 16,296 people who have side effects when taking Tafinlar from the FDA, and is updated regularly.

What is Tafinlar?

Tafinlar has active ingredients of dabrafenib mesylate. eHealthMe is studying from 16,304 Tafinlar users. Check the latest studies of Tafinlar.

What is Metastatic neoplasm?

Metastatic neoplasm (spreadable cancer tumour) is found to be associated with 605 drugs and 516 conditions by eHealthMe. Check the latest studies of Metastatic neoplasm.

On Jul, 13, 2026

16,296 people reported to have side effects when taking Tafinlar.
Among them, 23 people (0.14%) have Metastatic neoplasm.

Could Tafinlar cause Metastatic neoplasm?

Among these 23 people:

How long have people been on Tafinlar when they have Metastatic neoplasm? *

What is the gender of people who have Metastatic neoplasm when taking Tafinlar? *

female: 69.57 %
male: 30.43 %

What is the age of people who have Metastatic neoplasm when taking Tafinlar? *

What are other drugs people take besides Tafinlar? *

What are other side effects people have besides Metastatic neoplasm? *

High Blood Pressure: 13 people, 56.52%
Dyspnea Exertional: 13 people, 56.52%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 13 people, 56.52%
Malignant Neoplasm Progression (cancer tumour came back): 13 people, 56.52%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 13 people, 56.52%
Lung Disorder (lung disease): 13 people, 56.52%
Lung Cancer - Non-Small Cell (lung cancer): 13 people, 56.52%
Coughing Up Blood: 13 people, 56.52%
Renal Impairment (severely reduced kidney function): 13 people, 56.52%
Epigastric Discomfort: 13 people, 56.52%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 13 people, 56.52%
Malignant Melanoma (skin cancer rises from melancytes): 3 people, 13.04%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 2 people, 8.70%
Pain: 1 person, 4.35%
Neoplasm Progression (growth of tumour): 1 person, 4.35%
Neoplasm Malignant (cancer tumour): 1 person, 4.35%
Metastases To Bone (cancer spreads to bone): 1 person, 4.35%
Malignant Lymphoid Neoplasm (malignant growth or tumour caused by abnormal and uncontrolled cell division in lymph node): 1 person, 4.35%
High Blood Pressure: 1 person, 4.35%
Brain Cancer Metastatic: 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Tafinlar and have Metastatic neoplasm?

- Check whether Metastatic neoplasm is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tafinlar:

Tafinlar (16,304 reports)

Browse all side effects of Tafinlar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Metastatic neoplasm:

Metastatic neoplasm (605 drugs)

Browse all the conditions that are associated with Metastatic neoplasm:

Metastatic neoplasm (516 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dabrafenib mesylate (the active ingredients of Tafinlar) and Tafinlar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.